摘要
目的:探讨非血缘及人类白细胞抗原配型不合的异基因外周血造血干细胞移植时,环孢素A、麦考酚酸酯、抗胸腺细胞球蛋白、白细胞介素11及短程甲氨蝶呤联合预防急性移植物抗宿主病的疗效。方法:2004-09/2008-11海口市人民医院采用环孢素A等五联用药预防非血缘及血缘HLA配型不合异基因外周血造血干细胞移植患者13例。供受者HLA相合情况:非血缘供者7例,单倍型移植3例,人类白细胞抗原1个位点不合同胞供者3例。具体预处理方案为移植前7d开始,环孢素A5～10mg/(kg·d),12h静滴1次,2次/d,无呕吐后改为口服维持;移植前7d开始,麦考酚酸酯1次/d;移植前5d～移植前2d予抗胸腺细胞球蛋白2.5mg/(kg·d);移植前2d～移植后10d予白细胞介素11,1.5mg/d皮下注射;移植后1d予甲氨蝶呤15mg/m2,移植后3,6,11d各予甲氨蝶呤10mg/m2静脉滴注。临床若无移植物抗宿主病出现,3～6个月逐渐减量至停药,单倍型移植者适当延长。移植前3d,供者行重组人粒细胞集落刺激因子皮下注射,于用药第4,5天采集外周血干细胞,并分别于当天由锁骨下静脉输入患者体内,回输单个核细胞数为(7.82～9.11)×108/kg,CD34+细胞数为(2.9～7.7)×106/kg。结果:13例患者均获得造血重建,急性移植物抗宿主病的发生率为46%(6/13),Ⅲ～Ⅳ度急性移植物抗宿主病发生率为8%(1/13)。随访至2009-04,除1例患者尚未能到公共场所外,余12例目前均正常生活或工作。结论:环孢素A、麦考酚酸酯、抗胸腺细胞球蛋白、白细胞介素11及短程甲氨蝶呤联合预防急性移植物抗宿主病可获得较好的疗效。
OBJECTIVE： To study curative effect of the combination of cyclospodne A, mycophenolate mofetil, anti-thymocyte globulin, interleukin-11 and short-term methotrexate as acute graft-versus-host disease （aGVHD） prophylaxis on HLA-matched unrelated donor or HLA-mismatched related donor allogenic peripheral blood stem cell transplantation （AIIo-PBSCT）.
METHODS： Thirteen patients with haematological malignancies who underwent HLA-matched unrelated donor or HLA-mismatched related donor AIIo-PBSCT with the combination of cyclosporine A as aGVHD prophylaxis at Haikou Municipal People＇s Hospital from September to November 2008 were selected, including 7 of unrelated donor, 3 of haplotype transplantation, and 3 of l-locus mismatched. The conditioning regimen was performed at 7 days prior to transplantation, with cyclosporine A 5 10 mg/（kg·d）, 12 hours per time with twice per day. From day 7 prior to transplantation, mycophenolic acid was intravenous drip once per day, then 2.5 mg/（kg·d） antithymocyte globulin at days 5-2 prior to transplantation, 1.5 mg/d interleukin 11 was subcutaneous injected at day 2 prior to and 10 days after transplantation, followed by intravenous drip 15 mg/m2 amethopterin at day 1 and 10 mg/m2 at days 3, 6, 11 after transplantation. The drug doge was reduced and stopped gradually after 3 6 months, which could be prolonged for haplotype grafter. Recombinant human granulocyte colony-stimulating factor was injected subcutaneously at day 3 prior to transplantation, and PBSCT was collected at days 4 and 5 after medication, which was infused to patients with subclavian vein at the same day. In total （7.82-9.11）×10^8/kg mononuclearcell and （2.9-7.7）×10^6/kg CD34＋ cells were infused.
RESULTS： Hematopoiesis was rebuilt in all patients with 46.15% （6/13） aGVHD incidence rate, including 8 % （1/13） of Ⅲ-Ⅳ aGVHD. Up to April of 2009, all patients live and work as normal except one patient who can not visit public places.
CONCLUSION： The combination of cyc
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2009年第36期7189-7192,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
基金
2007年海南省自然科学基金(30724)~~
